Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

tual results may vary once the final and quality-controlled verification of data and analyses has been completed, the expense and uncertainty of obtaining regulatory approval, including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory approval is obtained, therapeutic products are generally subject to: stringent on-going governmental regulation, challenges in gaining market acceptance, and competition. Neurochem does not undertake any obligation to publicly update its forward-looking statements, whether as a result of new information, future events, or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.

    For further information, please contact:


    Lise Hebert, PhD                          Tel: (450) 680-4572

    Vice President, Corporate Communications
lhebert@neurochem.com

CONTACT: Lise Hebert, PhD, Vice President, Corporate Communications, (450)680-4572, lhebert@neurochem.com

Ticker Symbol: (:NRM.),(:NRMX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:12/1/2008)...EGO, Dec. 1 TargeGen has announced...s from a multi-center, US-based clinical,trial of...as been scheduled at,the 2008 American Society of...he presentation are as follows:, Title: ...oavailable, JAK2-Selective...
(Date:12/1/2008)...APOLIS, Dec. 1 Roche announced tod... differences in perceived pain and,discomfort ass...K blood,glucose monitoring systems and lancing de...indicated that, overall, the ACCU-CHEK Aviva and A...stems and the ACCU-CHEK Multiclix, ACCU-CHEK,Soft...
(Date:12/1/2008)...de study shows the Prox1 gene is a two-way switch ...cells to be reprogrammed so that they lose their i...ls , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-U...esearch Hospital have discovered that a certain di...dentity that it requires the constant expression o...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Embryos Discarded During IVF Create Stem Cell Lines 10220 1Embryos Discarded During IVF Create Stem Cell Lines 10220 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 1Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 3The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 1The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 2NutraCea Provides Update on Domestic Operations 10215 1NutraCea Provides Update on Domestic Operations 10215 2NutraCea Provides Update on Domestic Operations 10215 3
...atient Lung Cancer Diversity Study, CHICAGO, June ...,lung cancer is the leading cause of cancer death ...ed to be diagnosed,and 16,700 deaths expected this...leading cause of cancer death in Hispanic men and ...ic women.(ii),Researchers at Eli Lilly and Company...
...l CBR of 52% which compares favorably with,the act..., 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris I...n,endocrine therapy and oncology, today announced ...ed a poster outlining Phase 1 and,Phase 2 results ...ction inhibitor compound, for the treatment of pat...
Other Medicine Technology:Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
(Date:12/2/2008)...o Celebrate With Traditional Holiday Cuisine , ... Food Ministries ( www.angelfoodministries.com ), ...y food at low-costs, to anyone who wishes to parti...include a specialty Christmas Box which includes e...tion. Host sites are now taking orders throughout ...
(Date:12/2/2008)...l Deficiencies in Care for Individuals across the ... Members who recently sought expert medical consul...certainty about their initial diagnosis or course ... , The findings are based on clinical review...s a unique health benefit that calls upon top medi...
(Date:12/2/2008)...ion Highlights Need to Reduce Disparities in Menin... , , BETHESDA, Md., Dec. 2 ... (NFID) S.T.O.P. (Share. Teach. Outreach. Protec...he nation,s leading medical and advocacy organizat...adolescent meningococcal vaccination rates and to ...
(Date:12/2/2008)...it could aid shift workers, people affected by jet...) -- The experimental drug tasimelteon helps treat...fts, according to the results of two new clinical ... randomly assigned to receive either 10 milligrams...ebo. They were monitored for seven nights -- three...
Breaking Medicine News(10 mins):Health News:Angel Food Ministries to Distribute Holiday Grocery Relief 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:Drug Effective for Temporary Sleep Disruptions 2
...ormal breathing functions. Exposure to atmospheric...eart muscle during exercise in those with heart pr...ure to air pollution// with both heart disease and... the first to show how pollution can restrict the ...
...versity in Boston, a person's degree of inhibition...ies is tied to his or her likelihood of being over...--for example by choosing low-calorie foods--can h...tation to eat, according to lead investigator Dr. ...
...t common encountered among the mountaineers. Docto...rs are affected by altitude sickness and others ar...ung function may increase the risk of high altitud...e pulmonary edema (HAPE), can result when people c...
... consume wine in moderation have healthier lifesty...ther types of alcohol. It is well established tha...e health benefit,// chiefly in the form of reduced... may not be the alcohol itself, but linked lifesty...
Other Medicine News:Health News:Stop and think before you eat 2
Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products: